Peptides

Brain-protecting effects of GLP-2 and a combined GLP-2/GIP treatment in a mouse model of Parkinson’s disease

Updated

Abstract

Motor function was significantly improved in both the GLP-2 analogue and GLP-2/GIP dual agonist groups compared to the control group.

  • Both treatments reduced levels of the pro-inflammatory factors TNF-α and NF-κB.
  • A decrease in the pro-apoptotic protein Bax was observed with both treatments.
  • The anti-apoptotic protein Bcl-2 was upregulated in response to both treatments.
  • Abnormal accumulation of α-synuclein was reduced with both the GLP-2 analogue and the dual agonist.
  • The dual GLP-2/GIP receptor agonist demonstrated superior efficacy, suggesting enhanced neuroprotection.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of Competing Interest The authors do not declare any conflict of interest.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free